PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 28644233-13 2017 Western blot analysis of vatalanib-treated cells showed vascular endothelial growth factor and transforming growth factor-beta significantly reduced, but there was no alteration in p53 protein levels in HPFs. vatalanib 25-34 vascular endothelial growth factor A Homo sapiens 56-90 30382439-0 2019 A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. vatalanib 68-77 vascular endothelial growth factor A Homo sapiens 23-57 30382439-1 2019 Introduction Vatalanib is an oral receptor tyrosine kinase inhibitor that blocks all known VEGF, PDGF, and c-Kit receptors. vatalanib 13-22 vascular endothelial growth factor A Homo sapiens 91-95 30402031-9 2018 Vatalanib, VEGF inhibitor, was tested by our assay system. vatalanib 0-9 vascular endothelial growth factor A Homo sapiens 11-15 28644233-14 2017 CONCLUSIONS: These results indicate that vatalanib significantly suppressed the proliferation and migration of HPFs by decreasing vascular endothelial growth factor and transforming growth factor-beta. vatalanib 41-50 vascular endothelial growth factor A Homo sapiens 130-164 25993161-7 2015 For recurrent and aggressive tumors, inhibitors of the vascular endothelial growth factor (VEGF) pathway, such as vatalinib, bevacizumab, and sunitinib, showed signs of activity in small, uncontrolled studies, and prospective clinical studies will test the efficacy of the tetrahydroisoquinoline trabectedin and of SMO and AKT1 inhibitors. vatalanib 114-123 vascular endothelial growth factor A Homo sapiens 55-89 25993161-7 2015 For recurrent and aggressive tumors, inhibitors of the vascular endothelial growth factor (VEGF) pathway, such as vatalinib, bevacizumab, and sunitinib, showed signs of activity in small, uncontrolled studies, and prospective clinical studies will test the efficacy of the tetrahydroisoquinoline trabectedin and of SMO and AKT1 inhibitors. vatalanib 114-123 vascular endothelial growth factor A Homo sapiens 91-95 23700288-0 2013 A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). vatalanib 69-78 vascular endothelial growth factor A Homo sapiens 29-33 23508585-4 2013 Here, we combined IFN/5-FU therapy with the VEGF receptor-selective inhibitor PTK787/ZK222584 (PTK/ZK) and examined the antitumor effects and the mechanism of action. vatalanib 78-84 vascular endothelial growth factor A Homo sapiens 44-48 23508585-4 2013 Here, we combined IFN/5-FU therapy with the VEGF receptor-selective inhibitor PTK787/ZK222584 (PTK/ZK) and examined the antitumor effects and the mechanism of action. vatalanib 85-93 vascular endothelial growth factor A Homo sapiens 44-48 24939212-1 2014 PURPOSE: Vatalanib (PTK 787/ZK22584) is an oral poly-tyrosine kinase inhibitor with strong affinity for platelet-derived growth factor and vascular endothelial growth factor (VEGF) receptors. vatalanib 9-18 vascular endothelial growth factor A Homo sapiens 139-173 24939212-1 2014 PURPOSE: Vatalanib (PTK 787/ZK22584) is an oral poly-tyrosine kinase inhibitor with strong affinity for platelet-derived growth factor and vascular endothelial growth factor (VEGF) receptors. vatalanib 9-18 vascular endothelial growth factor A Homo sapiens 175-179 23700288-0 2013 A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). vatalanib 80-86 vascular endothelial growth factor A Homo sapiens 29-33 23700288-0 2013 A phase II study of the oral VEGF receptor tyrosine kinase inhibitor vatalanib (PTK787/ZK222584) in myelodysplastic syndrome: Cancer and Leukemia Group B study 10105 (Alliance). vatalanib 87-95 vascular endothelial growth factor A Homo sapiens 29-33 23700288-2 2013 Vatalanib (PTK787/ZK222584; Novartis and Schering AG) inhibits receptor tyrosine kinases of vascular endothelial growth factor, platelet derived growth factor and c-Kit. vatalanib 0-9 vascular endothelial growth factor A Homo sapiens 92-126 23700288-2 2013 Vatalanib (PTK787/ZK222584; Novartis and Schering AG) inhibits receptor tyrosine kinases of vascular endothelial growth factor, platelet derived growth factor and c-Kit. vatalanib 11-17 vascular endothelial growth factor A Homo sapiens 92-126 23700288-2 2013 Vatalanib (PTK787/ZK222584; Novartis and Schering AG) inhibits receptor tyrosine kinases of vascular endothelial growth factor, platelet derived growth factor and c-Kit. vatalanib 18-26 vascular endothelial growth factor A Homo sapiens 92-126 23325408-9 2013 Effects of VEGF on colocalization were blocked by the VEGF receptor antagonists vatalanib (240 nM) and dasatinib (6.3 nM). vatalanib 80-89 vascular endothelial growth factor A Homo sapiens 11-15 23325408-9 2013 Effects of VEGF on colocalization were blocked by the VEGF receptor antagonists vatalanib (240 nM) and dasatinib (6.3 nM). vatalanib 80-89 vascular endothelial growth factor A Homo sapiens 54-58 20682704-2 2010 We had shown previously that the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 (PTK/ZK) is a competitive aromatase inhibitor in vitro. vatalanib 73-79 vascular endothelial growth factor A Homo sapiens 33-37 22910317-1 2012 BACKGROUND: Pharmacological inhibitors of vascular endothelial growth factor (VEGF) receptors, like vatalanib, have been tested in randomised trials (CONFIRM (Colorectal Oral Novel therapy For the Inhibition of Angiogenesis and Retarding of Metastases) 1 and 2) in colorectal cancer showing activity in a subgroup of patients with high serum LDH expression. vatalanib 100-109 vascular endothelial growth factor A Homo sapiens 42-76 22910317-1 2012 BACKGROUND: Pharmacological inhibitors of vascular endothelial growth factor (VEGF) receptors, like vatalanib, have been tested in randomised trials (CONFIRM (Colorectal Oral Novel therapy For the Inhibition of Angiogenesis and Retarding of Metastases) 1 and 2) in colorectal cancer showing activity in a subgroup of patients with high serum LDH expression. vatalanib 100-109 vascular endothelial growth factor A Homo sapiens 78-82 20682704-2 2010 We had shown previously that the VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 (PTK/ZK) is a competitive aromatase inhibitor in vitro. vatalanib 80-88 vascular endothelial growth factor A Homo sapiens 33-37 19435899-0 2009 The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. vatalanib 58-64 vascular endothelial growth factor A Homo sapiens 4-38 20404549-3 2010 Vatalanib is a selective inhibitor of VEGF receptors 1-3. vatalanib 0-9 vascular endothelial growth factor A Homo sapiens 38-42 19945857-2 2010 PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable for long-term therapy of pathologic tumour neovascularisation. vatalanib 7-15 vascular endothelial growth factor A Homo sapiens 48-52 19945857-2 2010 PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable for long-term therapy of pathologic tumour neovascularisation. vatalanib 7-15 vascular endothelial growth factor A Homo sapiens 136-140 19945857-2 2010 PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable for long-term therapy of pathologic tumour neovascularisation. vatalanib 25-34 vascular endothelial growth factor A Homo sapiens 48-52 19945857-2 2010 PTK787/ZK222584 (PTK/ZK, vatalanib), a multiple VEGF receptor inhibitor, blocks the intracellular tyrosine kinase activity of all known VEGF receptors and is therefore suitable for long-term therapy of pathologic tumour neovascularisation. vatalanib 25-34 vascular endothelial growth factor A Homo sapiens 136-140 19435899-0 2009 The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase. vatalanib 65-73 vascular endothelial growth factor A Homo sapiens 4-38 18484796-9 2008 Another promising therapeutic strategy is the blockade of VEGF effects by inhibition of the tyrosine kinase cascade downstream from the VEGF receptor; such therapies currently in development include vatalanib, TG100801, pazopanib, AG013958 and AL39324. vatalanib 199-208 vascular endothelial growth factor A Homo sapiens 58-62 19622904-2 2009 Some of them are already available in human trials or even approved vascular epithelial growth factor (VEGF) blockers such as Macugen, Lucentis, Avastin, VEGF Trap-Eye and Cand5; VEGF receptor blockers such as TG100801, vatalanib, pazopanib, Sirna-027 and a vaccine approach; inflammation inhibitors and immunosuppressants such as Retaane, Kenalog, ARC1905, POT-4, OT-551. vatalanib 220-229 vascular endothelial growth factor A Homo sapiens 103-107 19668729-11 2008 Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. vatalanib 45-54 vascular endothelial growth factor A Homo sapiens 86-90 17470687-5 2007 We limit ourselves to the two agents that have been tested extensively in phase III trials: bevacizumab and vatalanib, a small molecule tyrosine kinase inhibitor against VEGF receptors. vatalanib 108-117 vascular endothelial growth factor A Homo sapiens 170-174 17846007-5 2007 This review summarizes efficacy and safety data of two antiangiogenic agents, bevacizumab (a monoclonal antibody inhibiting VEGF) and vatalanib (a tyrosine kinase inhibitor of VEGF), assessed in phase III trials in metastastic colorectal cancer. vatalanib 134-143 vascular endothelial growth factor A Homo sapiens 176-180 16882767-1 2006 Vatalanib (PTK787/ZK-222584) is a new oral antiangiogenic molecule that inhibits all known vascular endothelial growth factor receptors. vatalanib 0-9 vascular endothelial growth factor A Homo sapiens 91-125 17628122-10 2007 Receptor tyrosine kinase inhibitors, such as vatalanib, inhibit downstream effects of VEGF, and have been effective in the treatment of CNV in early studies. vatalanib 45-54 vascular endothelial growth factor A Homo sapiens 86-90 15708274-4 2005 The vascular endothelial growth factor receptor tyrosine kinase inhibitor PTK787/ZK222584 (50 mg/kg body weight b.i.d.) vatalanib 74-80 vascular endothelial growth factor A Homo sapiens 4-38 16600618-2 2006 Many drugs that target human tumors, like bevacizumab and some VEGF-receptor tyrosine-kinase inhibitors (e.g., BAY 43-9006, SU11248 and PTK787/ZK222584) have been studied in clinical trials, with favorable toxicity reports and encouraging results in advanced colorectal cancer, renal cell cancer, breast cancer and non-squamous non-small cell lung cancer, either combined with chemotherapy, or in monotherapy. vatalanib 143-151 vascular endothelial growth factor A Homo sapiens 63-67 16407877-5 2006 Furthermore, addition of vatalanib, a kinase inhibitor developed as a VEGF receptor-selective agent, to chemotherapy did not show a similar benefit in metastatic colorectal cancer patients. vatalanib 25-34 vascular endothelial growth factor A Homo sapiens 70-74 11747347-0 2001 Effect of VEGF receptor inhibitor PTK787/ZK222584 [correction of ZK222548] combined with ionizing radiation on endothelial cells and tumour growth. vatalanib 34-40 vascular endothelial growth factor A Homo sapiens 10-14 14706172-0 2003 Current studies with PTK787, an oral inhibitor of vascular endothelial growth factor in colorectal cancer. vatalanib 21-27 vascular endothelial growth factor A Homo sapiens 50-84 15479483-6 2004 Vatalanib (PTK787/ZK222584) is an oral antiangiogenic tyrosine kinase inhibitor of the VEGF receptor. vatalanib 0-9 vascular endothelial growth factor A Homo sapiens 87-91 15479483-6 2004 Vatalanib (PTK787/ZK222584) is an oral antiangiogenic tyrosine kinase inhibitor of the VEGF receptor. vatalanib 11-17 vascular endothelial growth factor A Homo sapiens 87-91 15479483-6 2004 Vatalanib (PTK787/ZK222584) is an oral antiangiogenic tyrosine kinase inhibitor of the VEGF receptor. vatalanib 18-26 vascular endothelial growth factor A Homo sapiens 87-91 15333517-10 2004 The VEGF-receptor antagonist PTK787 also selectively ablated the VEGF-induced angiogenic effect without inhibiting the HGF-induced response, demonstrating the sensitivity of the system to detect modulation of distinct signal cascades. vatalanib 29-35 vascular endothelial growth factor A Homo sapiens 4-8 15333517-10 2004 The VEGF-receptor antagonist PTK787 also selectively ablated the VEGF-induced angiogenic effect without inhibiting the HGF-induced response, demonstrating the sensitivity of the system to detect modulation of distinct signal cascades. vatalanib 29-35 vascular endothelial growth factor A Homo sapiens 65-69 12483548-8 2002 VEGF-A-mediated increases in vascular permeability in perfused mesenteric microvessels in vivo were reversibly abolished by both ZM323881 and the class III receptor tyrosine kinase inhibitor PTK787/ZK222584. vatalanib 191-197 vascular endothelial growth factor A Homo sapiens 0-6 12483548-8 2002 VEGF-A-mediated increases in vascular permeability in perfused mesenteric microvessels in vivo were reversibly abolished by both ZM323881 and the class III receptor tyrosine kinase inhibitor PTK787/ZK222584. vatalanib 198-206 vascular endothelial growth factor A Homo sapiens 0-6 11747347-6 2001 These results support the model of a cooperative anti-tumoral effect of angiogenesis inhibitor and irradiation and show that the orally bioavailable VEGF receptor tyrosine kinase inhibitor PTK787/ZK222584 is suitable for combination therapy with irradiation. vatalanib 196-204 vascular endothelial growth factor A Homo sapiens 149-153